LONDON — Sanofi on Monday named a new leader for its research and development efforts, as the French pharma company looks to reinvigorate its pipeline under new CEO Belén Garijo.
Paulo Fontoura will become global head of R&D for Sanofi’s pharma work starting Sept. 1. A neurologist by training, Fontoura was most recently the chief medical officer at Xaira Therapeutics, an AI-focused drug discovery company. He previously spent more than 15 years at Roche.
Fontoura is replacing Houman Ashrafian, who joined Sanofi in 2023 following years as a health care investor. Sanofi said Ashrafian “has decided to pursue an opportunity outside the company.”
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.